Clinic
Oc Urgentcare Medical Group Incorporated
Oc Urgentcare Medical Group Incorporated was paid $13.98M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 34% of everything it billed.
33Billing provider infoOC URGENTCARE MEDICAL GROUP INCORPORATED
ANAHEIM, CA 92804
ANAHEIM, CA 92804
33aNPI1083940597assigned 10/19/2009
33bProvider typeUrgent Care Clinic/Center
28Total paid$13.98M
24GClaims303,356
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in California
Rank by total paid#18 of 284
Median peer was paid$147K
This provider vs. median95×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,493 | $1.52M | |
| 2019 | 30,424 | $1.70M | |
| 2020 | 25,755 | $1.26M | |
| 2021 | 36,681 | $1.94M | |
| 2022 | 50,489 | $2.51M | |
| 2023 | 65,740 | $2.62M | |
| 2024incomplete | 67,774 | $2.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 85,291 | 78,316 | $4.75M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 32% | 95,734 | 84,991 | $4.52M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 20% | 49,179 | 48,787 | $2.78M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 7.2% | 15,176 | 15,069 | $1.01M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.1% | 5,526 | 5,441 | $293K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.1% | 12,127 | 10,817 | $289K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,343 | 3,223 | $127K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,523 | 6,452 | $35K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,650 | 3,394 | $32K |
| 93000 | <1% | 2,149 | 2,109 | $30K | |
| 81002 | <1% | 5,919 | 5,679 | $25K | |
| 86769 | <1% | 663 | 652 | $21K |
28 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,658 | $15K |
| 99070 | <1% | 4,340 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,080 | $8K |
| 81025 | <1% | 2,246 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,573 | $7K |
| 99000 | <1% | 702 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 958 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 797 | $4K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 31 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 28 | $2K |
| 36416 | <1% | 414 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $997.57 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 16 | $820.96 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 95 | $760.35 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 156 | $670.25 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 16 | $657.00 |
| 69209 | <1% | 195 | $537.96 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 705 | $471.12 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,183 | $440.94 |
| 81000 | <1% | 29 | $411.74 | |
| 97602 | <1% | 60 | $296.79 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 131 | $237.41 |
| 10060 | <1% | 14 | $236.37 | |
| 82962 | <1% | 86 | $127.67 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 27 | $119.97 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 452 | $77.68 |
| G8783 | Normal blood pressure reading documented, follow-up not required | <1% | 45 | $54.08 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 12 | $0.35 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOTHMAN, MOUSTAFA (CFO)